Osteoporosis Therapeutics: Market Research Report

Date: May 1, 2012
Pages: 455
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OCF1CC73426EN
Leaflet:

Download PDF Leaflet

Osteoporosis Therapeutics: Market Research Report
This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following Therapeutic Classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, and MAB (Denosumab).

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 49 companies including many key and niche players such as Abbott Laboratories, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Wyeth, Sanofi-Aventis SA, Servier SA, Unigene Laboratories, Inc., and Warner Chilcott plc.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Bisphosphonates
Hormone Replacement Therapy/Estrogen Replacement Therapy
Estrogens
Estrogens/Progesterones
Calcitonins
Selective Estrogen Receptor Modulators (SERMs)
Other Therapeutics

II. EXECUTIVE SUMMARY

1.OUTLOOK

Generic Incursion Drubs Market Revenues Worldwide
Novel Therapies to Recuperate Market Growth
Denosumab Bodes Significant Market Opportunities

2.MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE

Bisphosphonates
The leading Therapeutic Market – Only for Now
ERT Drugs
Ups and Downs in the ERT Market
SERMs (Selective Estrogen Receptor Modulators)
Market Overview
Calcitonins
Market Overview
Monoclonal Antibodies (Denosumab)
Market Overview
New Drugs/Drug Classes in Pipeline
End-Stage Therapies (Under Development) for Osteoporosis Prevention/Cure
SERMs
Eli Lilly Drops Clinical Study of Arzoxifene for Bone Loss
Pfizer Intends to Withdraw NDAs for Fablyn
Bisphosphonates
Zoledronic Acid
Pamidronate
Calcitonin
Emisphere’s Oral Calcitonin Candidate Fails to Clear Clinical Trials
Parathyroid Hormone (PTH)
Novartis Terminates Clinical Study of Oral Formulation of PTH1-34
Monoclonal Antibodies - Denosumab

Table 1. Comparison of Major Osteoporosis Drugs in Reducing Risk of Fracture

RANK Ligand
Combination Therapy
Others
Cathepsin K inhibitors
Merck Releases New Data for Odanacatib

3.MARKET DYNAMICS

Facts & Figures: The Osteoporosis Primacy
Snapshots

Table 2. Prevalence of Osteoporosis and Osteopenia in Major Markets including US, Germany, Italy, France, UK, Spain and Japan: 2003-2013 (In Millions) (includes corresponding Graph/Chart)

Osteoporosis Therapeutics: An Evolutionary Scan
Currently Available Drugs for Osteoporosis Treatment
“A Sketch of the Present Industry Scenario”
Factors Influencing Demand
Altering Competitive Landscape in Osteoporosis Market

Table 3. Leading Drugs in the Global Osteoporosis Therapeutics Market (2006-2009): Value Sales for Actonel, Fosamax, Evista, Boniva, Forteo and Aclasta/Reclast in US$ Million (includes corresponding Graph/Chart)
Table 4. Leading Osteoporosis Therapies and its Cost per Day

Market Trends and Issues
Poor Disease Detection - A Major Market Constraint
Reluctance to Undergo HRT to Increase Osteoporosis Burden
Patent Expiries to Impact Market Growth
Limitations Bog Down Current Therapies
Growth Opportunities Galore for New Drugs
Bisphosphonates to Lose Market Value
Poor Compliance Mars Use of Bisphosphonates
Side Effects of HRT Fuel Natural Alternatives Sales
Bone Formation Drugs Augur New Prospects
A Sneak Into Various Options in Antiresorptives, Anabolic Therapeutics
Estrogen Replacement Therapy: Will Dosing Make a Difference?
Is Prevention Always Better Than Cure?
Peptide-Based Osteoporosis Therapy Gaining Ground
Polymorphism- A Potent Diagnostic Marker
Bisphosphonates – The Other Side
Efficacy of Evista under the Scanner

4.PRODUCT OVERVIEW

The “Silent Thief”
An Introduction to Bone Physiology
How Osteoporosis Steps In
Osteoporosis: Major Types
Primary Osteoporosis
Secondary Osteoporosis
Osteoporosis - The Aftermath
Prevention: The Only Better Way Out
Osteoporosis Therapies: A Cursory Glance
Non-drug Therapy
Drug Therapy
Major Osteoporosis Therapeutic Classes: A Brief Review
Bisphosphonates
Classification of Bisphosphonates
AlendronateII-24Etidronate
Risedronate
Calcitonins: A Relatively Safer Therapeutic
What It Is
What It Does
Major Types
Salmon Calcitonin
SERM: A Breakthrough
Raloxifene: Most Widely Approved SERM
SERMs: The Positive Angle
SERMs: The Negative Side
Hormone Replacement Therapy/Estrogen Replacement Therapy: The Longstanding Therapeutic
ERT: The Positive Side
The Negative Angle to ERT
Tereparatide: The First Anabolic Agent
Composition
Forteo: A Leading Brand
Major Osteoporosis Therapeutic Classes at a Glance
Osteoporosis Therapeutics: A Peek into the Major Brands

5.PRODUCT INTRODUCTIONS/APPROVALS

Pfizer Launches Bazedoxifene in Japan
Daiichi Files for Approval of Denosumab in Japan
Amgen Obtains FDA Approval for Prolia (denosumab) in Treating Post-Menopausal Osteoporosis
Amgen Obtains EC Approval for Marketing Prolia®
Teva to Launch Generic Version of Evista
Eli Lilly Obtains FDA Approval for Expanded Indication of Forteo®
WANBURY Introduces a Calcium Brand, CDENSE, in India
Yissum Launches New Compound for Osteoporosis Treatment
Novartis Bags US Approval for Reclast
Wyeth Obtains EC Approval for Conbriza™
Ono and Astellas Introduce Bonoteo in Japan
European Commission Grants Approval to Pfizer for FABLYN® Tablets

6.PRODUCT INTRODUCTIONS/INNOVATIONS – A HISTORIC PERSPECTIVE BUILDER

MDRNA Receives Tentative Approval for New Osteoporosis Drug
Novartis Receives EU Approval for Aclasta
Sun Pharmaceutical Industries Receives Approval for Fosamax (S)
Dr Reddy's Obtains Approval for Production and Marketing of Generic Fosamax
Aurobindo Pharma Obtains Approval for Introducing Sodium Tablets in the US
Procter & Gamble Obtains Approval for Actonel
Eli Lilly Obtains European Commission Approval for FORSTEO®
Ranbaxy Collaborates with Virchow to Introduce Bonista Teriparatide Injection
Barr Pharmaceuticals Subsidiary Introduces Generic Osteoporosis Drug
Teva Pharmaceutical Industries Obtains Approval for Generic Fosamax® Tablets
P&G Receives FDA Approval for New Dosage of Actonel
Takeda Introduces Benet® for Osteoporosis Treatment
Labtec Obtains Approval to Market Hormone Replacement Patch in Europe
Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA
Merck’s New Dosage of FOSAMAX PLUS D Gains FDA Approval
Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug
Roche and GlaxoSmithKline Introduce Bonviva
GlaxoSmithKline and Roche Co-Promoted Boniva Receives FDA Approval
Nycomed’s Preotact Recommended for Approval in Europe
Procter & Gamble and Sanofi-Aventis’ Actonel Approved for Male Osteoporosis
Upsher-Smith Laboratories Rolls Out Fortical Nasal Spray
Teva Receives Tentative FDA Approval for Risedronate Sodium Tablets
GlaxoSmithKline and Roche Receive Approval for Bonviva in Switzerland
Roche’s Once-a-month Bisphosphonate Gets FDA Nod
Actonel with Calcium® Obtains FDA Approval
FDA Approves Unigene’s Nasal Calcitonin

7.MAJOR CLINICAL TRIALS/FINDINGS

Azelon Pharmaceuticals Completes Phase II trails for Comparing Nasal Spray Formulation of Teriparatide with Forteo, Administered Subcutaneously
GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics
Radius Initiates Phase II Trials for BA058
Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon Calcitonin
Medivir Initiates First Human Trials for MIV-701
Osteologix Begins Phase II Trial of NB S101
Zelos and Nektar Initiates Phase I Clinical Trial of Ostabolin-C™
Acceleron Initiates Phase I Clinical Trial of ACE-011
Positive Results from Reclast Clinical Trials

8.RECENT INDUSTRY ACTIVITY

Sanofi Amends Agreement with Warner Chilcott for Actonel®
Oramed and Laser Detect Systems Ink Joint Venture Agreement
Orchid Chemicals and Pharmaceuticals, and Alvogen Ink Agreement
Abbott Takes Over Solvay Pharmaceuticals
Novartis Obtains Clearance To Continue Clinical Trials on Oral Calcitonin
Merck Merges with Schering-Plough
Warner Chilcott Acquires Pharmaceuticals Business of P&G
Unigene Laboratories Signs Agreement with Tarsa Therapeutics
Bone Medical Obtains Formal Response from FDA for Capsitonin’s IND
US District Court Confirms Validity of Eli Lilly’s Patent for Evista®
US District Court Confirms Validity of Unigene's Patent for Fortical®
Ajinomoto Announces Japan Rights for Risedronate Hydrate from P&G
Amgen and GSK Join Forces to Market Denosumab
Galapagos-Lily Collaboration Achieves Milestone in Osteoporosis Treatment
EffRx and Nycomed Sign Licensing Deal for EX101
Pfizer Takes Over Wyeth
Pfizer Obtains Complete Response Letter from US FDA for Lasofoxifene
Wockhardt Signs Agreement with DSM Nutritional for Launch of Bonistein in India

9.STRATEGIC CORPORATE DEVELOPMENTS – A HISTORIC PERSPECTIVE BUILDER

MorphoSys and Galapagos Form Long-Term Development Alliance
Daiichi Sankyo Establishes Ireland-Based Subsidiary
Merck and Japan Tobacco Sign Global Licensing Agreement for JTT-305
Zelos Therapeutics Signs Agreements for Registration Study of ZT-031
NuVasive Takes Over Osteocal Biologics Business of Osiris Therapeutics
Eli Lilly and TransPharma Medical Sign Licensing and Development Agreement
Bone Medical Joins Hands with Hyundai Pharm. for Marketing PTH in South Korea
Eli Lilly to Acquire Osteoporosis Drug Patch from TransPharma Medical
Wyeth Obtains Approvable Letter from FDA for Bazedoxifene
Daiichi Sankyo Establishes Subsidiary in Turkey
Aegis Therapeutics and Zelos Therapeutics Sign Agreement for ZT-031
Teijin Pharma Obtains a License from Dong Wha Pharm for DW-1350
IOF Signs Agreements with Chinese Organizations for Osteoporosis Treatment
DAIICHI SANKYO Takes Over EVISTA® from Eli Lilly
Daiichi Sankyo Acquires Developing and Marketing Rights for Denosumab in Japan
Schering-Plough Acquires Organon BioSciences
Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline
Alethia and Emerillon Collaborate on Osteoporosis Therapies
Ipsen Enters into Co-marketing Agreement with MSD
Unigene Enters into Agreement with Novartis
Pharming Group Granted Subsidies to Develop Osteoporosis Drugs
Procter & Gamble Terminates Nasal Spray Collaboration with Nastech Pharmaceutical
Pharming Group Acquires DNage
Amgen Acquires Abgenix
P&G Licenses Osteoporosis Nasal Spray Rights from Nastech
Eli Lilly to Close Basingstoke Plant
Galapagos Acquires Drug Discovery Platform of Discovery Partners
Duravest Acquires Bio-Magnetic Therapy
Galapagos Acquires ProStrakan’s ProSkelia
Roche Inks a Marketing Agreement with Elder Pharma
Chugai and Taisho Sign a Joint Development and Marketing Agreement
Theragenex Signs a Licensing Agreement with Zylera
Radius Acquires Licensing Agreement for Eisai’s SERMs
Alkermes Partners with Eli Lilly to Develop and Market PTH Formulation
Radius Acquires Exclusive Rights to Karo Bio’s SARMS
Unigene Enters into Agreement with Tzamal Bio
Galapagos Acquires Inpharmatica
Bio-Rad Acquires Provalis Medical Diagnostics Operations
Daiichi Sankyo to Market Evista in Europe
Biocon Acquires Nobex
Radius and Ipsen Enters into Licensing Agreement
Novartis Acquires Hexal AG
Nippon Chemiphar Signs Agreement with Velcura Therapeutics
Biopotential Capital Acquires Osta Biopharma
Dnage Commences DNA Research Programme for Osteoporosis Therapeutics
Nastech Initiates Phase I Study of PTH 1-34

10.FOCUS ON SELECT GLOBAL PLAYERS

Eli Lilly and Company (US)
F.Hoffmann-La Roche Ltd (Switzerland)
Merck & Co., Inc. (US)
Novartis AG (Switzerland)
Pfizer, Inc. (US)
Wyeth (US)
Sanofi SA (France)
Servier SA (France)
Unigene Laboratories, Inc. (US)
Warner Chilcott plc (Ireland)

11.GLOBAL MARKET PERSPECTIVE

Table 5. World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 6. World Historic Review for Osteoporosis Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 7. World 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 8. World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 9. World Historic Review for Bisphosphonates by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 10. World 15-Year Perspective for Bisphosphonates by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 11. World Recent Past, Current & Future Analysis for ERT Drugs by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 12. World Historic Review for ERT (Estrogen Replacement Therapy) Drugs by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 13. World 15-Year Perspective for ERT (Estrogen Replacement Therapy)Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 14. World Recent Past, Current & Future Analysis for SERMs by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 15. World Historic Review for SERMs (Selective Estrogen Receptors Modulators) by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 16. World 15-Year Perspective for SERMs (Selective Estrogen Receptors Modulators) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 17. World Recent Past, Current & Future Analysis for Calcitonins by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 18. World Historic Review for Calcitonins by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 19. World 15-Year Perspective for Calcitonins by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 20. World Recent Past, Current & Future Analysis for MAB (Denosumab) by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 21. World 15-Year Perspective for MAB (Denosumab) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. Market Analysis
Industry Overview
Osteoporosis in the US: An Insight
Osteoporosis – An Underserved Market?
Statistical Review

Table 22. Osteoporosis Prevalence in Post-Menopause Women (includes corresponding Graph/Chart)
Table 23. Number of Osteoporosis Patients Undergoing Osteoporosis Therapies (In Thousands) (includes corresponding Graph/Chart)

Osteoporosis Prescription Market

Table 24. US Osteoporosis Prescription Market (2004-2006): Percentage Share of Leading Drugs - Fosamax, Actonel, Evista, Boniva, Forteo and Others (includes corresponding Graph/Chart)

Competitive Scenario

Table 25. Leading Players in the US Osteoporosis Market (2004 – A Historic Review) – Market Share by Value Sales for Merck, Eli Lilly, Procter & Gamble/ Sanofi, and Others (includes corresponding Graph/Chart)

Competitive Review by Segment – A Historic Review
Bisphosphonates

Table 26. Leading Players in the US Bisphosphonates Market (2004) – Market Share by Value Sales for Merck and Procter & Gamble/ Sanofi (includes corresponding Graph/Chart)

SERMs
Calcitonins
Patent Expiry of Major Osteoporosis Drugs
B. Market Analytics

Table 27. The US Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB (Denosumab) and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 28. The US Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 29. The US 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB (Denosumab) and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2.JAPAN

Market Analytics

Table 30. Japanese Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab)Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 31. Japanese Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 32. Japanese 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3.EUROPE

A. Market Analysis
Forteo: The First Anabolic Agent in Europe
European Regulatory Restricts HRT
Calcitonin Embraces New Label

Table 33. European Market for Osteoporosis Therapeutics (2005– A Historic Review): Market Share of Leading Players - Novartis, Merck, Wyeth, Novo Nordisk, Organon, Procter & Gamble, Schering, Solvay and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 34. European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Geographic Region – France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 35. European Historic Review for Osteoporosis Therapeutics by Geographic Region – France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 36. European 15-Year Perspective for Osteoporosis Therapeutics by Geographic Regions – Percentage Breakdown of Dollar Sales for France, Germany, The UK, Italy, Spain, and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 37. European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 38. European Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 39. European 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3A.FRANCE

Market Analytics

Table 40. French Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 41. French Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 42. French 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3B.GERMANY

Market Analytics

Table 43. German Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 44. German Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 45. German 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3C.ITALY

Market Analytics

Table 46. Italian Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 47. Italian Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 48. Italian 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3D.THE UNITED KINGDOM

A. Market Analysis

Table 49. Osteoporosis Population in the UK: 2004-2009

B. Market Analytics

Table 50. The UK Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 51. The UK Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 52. The UK 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3E.SPAIN

Market Analytics

Table 53. Spanish Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 54. Spanish Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 55. Spanish 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3F.REST OF EUROPE

A. Market Analysis
Romania
B. Market Analytics

Table 56. Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 57. Rest of Europe Historic Review for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 58. Rest of Europe 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4.REST OF WORLD

A. Market Analysis
Prevalence of Osteoporosis in Various Region - At a Glance
Korea

Table 59. Korean Osteoporosis Therapeutics Market by Leading Brands (2005 - A Historic Review): Percentage Share Breakdown by Dollar Sales for Fosamax, Atonel, Alend, Maxmarvil, and Others (includes corresponding Graph/Chart)

China
B. Market Analytics

Table 60. Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 61. Rest of World Historic Review for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 62. Rest of World 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 49 (including Divisions/Subsidiaries - 63)
The United States (24)
Canada (4)
Japan (7)
Europe (21)
- France (3)
- Germany (3)
- The United Kingdom (3)
- Italy (2)
- Spain (1)
- Rest of Europe (9)
Asia-Pacific (Excluding Japan) (5)
Middle East (2)

Ask Your Question

Osteoporosis Therapeutics: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: